Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phoqus to advance Chronocort into phase II trials for adrenal insufficiency

Oct. 18, 2006

End-of-phase II meeting requested for Diamyd

Oct. 17, 2006

TPM-02/insulin delivers insulin through skin in phase I trial

Oct. 17, 2006

Recent patents disclose novel agents for obesity and disorders of lipoprotein metabolism

Oct. 16, 2006

MGA-031 awarded orphan drug status for recent-onset type 1 diabetes mellitus

Oct. 13, 2006

Grapefruit juice consumption could help to prevent osteoporosis

Oct. 11, 2006

New agents for endocrine-related disorders imparted in recent patent literature

Oct. 11, 2006

Aegerion signs crosslicense agreement for MTP inhibitors

Oct. 11, 2006

Pharming receives orphan product grant for Rhucin

Oct. 10, 2006

Gabapentin GR study in diabetic peripheral neuropathy completes enrollment

Oct. 10, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...